Pluristyx

What Pluristyx does

Pluristyx is a Seattle-based, privately held biotechnology company founded in 2018 that operates an integrated induced pluripotent stem cell (iPSC) platform for therapeutic developers. Its core product offering combines off-the-shelf cell banks (PluriBank™), high-density cryopreserved Ready-to-Differentiate® (RTD®) formats, supporting reagent kits (PluriKit™, PluriFreeze™ cryopreservation, PluriForm™ for organoids), and proprietary gene-editing technologies: FailSafe® (a drug-inducible HSV-TK suicide switch tied to cell division loci for selective elimination of proliferating cells via ganciclovir), iACT Stealth Cells™ (immune cloaking without disrupting HLA expression to enable universal allogeneic therapies), and footprint-free mRNA-based reprogramming. The platform is positioned for regulatory compliance including FDA Drug Master File registration and 21 CFR 1271/210/211 standards, with international IP coverage including a 2026 Japan patent allowance for engineered synthetic mRNA constructs that reduce iPSC line generation time to under 30 days from 90+.

The company monetizes across four revenue streams: one-time and licensed sale of iPSC lines (RUO and GMP clinical grade, gene-edited and unmodified), technology licensing through Research Evaluation Agreements (a 12–18 month Try-Before-You-Buy model), professional development and GMP manufacturing services (process/analytical development, cell banking, scale-up, tech transfer), and consumables sales (PluriFreeze, PluriKit, PluriForm). Primary customers are biopharmaceutical and biotech firms developing iPSC-derived allogeneic cell therapies for regenerative medicine, neurological disease, islet cell replacement, and Type 1 Diabetes, with secondary demand from academic and research institutions. Distribution combines direct enterprise sales with channel partnerships (Teknova for PluriFreeze in US/Canada, Charles River for research-grade lines, and a reciprocal arrangement with Qkine).

Commercially, Pluristyx is in an active build-out phase: it has executed multiple strategic partnerships with CDMOs (Made Scientific, National Resilience, Mytos, ARMI/BioFabUSA), secured non-dilutive funding from Breakthrough T1D for a Type 1 Diabetes program, co-led by BroadOak Capital Partners and BioLife Solutions across two funding rounds, launched the Organoid COMMONS consortium for organoid standards, and integrated CellVoyant's AI foundation models for label-free cell analytics. The company is led by CEO Benjamin Fryer (Semma Therapeutics co-inventor, 14 years in stem cell science), COO Jason Carstens (former Fred Hutchinson, Nohla, and CMC Biologics), and Chief Commercial & Development Officer Priya Baraniak.

Name

Pluristyx

Legal name

Pluristyx, Inc.

Website

https://pluristyx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Pluristyx is a Seattle-based biotechnology company that provides an integrated iPSC platform — off-the-shelf cell banks, proprietary gene-editing (FailSafe® safety switch, iACT™ immune cloaking), mRNA reprogramming, and GMP manufacturing services — to biotech and pharma developers of iPSC-derived cell therapies.

Ownership category

akta.pro rank

Product category

Cell Therapy Products and Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

Keywords

• Induced pluripotent stem cells
• Cell therapy development
• GMP cell manufacturing
• Stem cell banking
• Cryopreservation consumables

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. iPSC Product Sales: Sale of off-the-shelf and custom iPSC lines including research grade (RUO) and GMP clinical grade cell banks, gene-edited lines with FailSafe and iACT technologies, and differentiated cell products.
2. Development Services: Process and analytical development services, GMP manufacturing services, cell line development and banking, and scale-up services for iPSC-based therapies.
3. Technology Licensing: Licensing of proprietary technologies including FailSafe, iACT Stealth Cells, and mRNA reprogramming through Research Evaluation Agreements followed by commercial licenses.
4. Consumables Sales: Sale of PluriFreeze cryopreservation products, PluriKit reagent bundles, and PluriForm organoid kits for iPSC culture and manufacturing workflows.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Pluristyx provides off-the-shelf and custom induced pluripotent stem cell (iPSC) lines, Ready-to-Differentiate (RTD) and GMP cell banks, supporting reagent kits (PluriKit, PluriFreeze, PluriForm), and proprietary gene-editing technologies (FailSafe safety switch and iACT Stealth Cells immune cloaking) for cell and gene therapy developers. The company also delivers process development, custom iPSC generation, and GMP manufacturing services to accelerate iPSC-derived cell therapy programs to IND and commercialization under a Try-Before-You-Buy Research Evaluation Agreement licensing model.

Product overview

Pluristyx offers a unified iPSC platform combining proprietary products and services for cell therapy development. The core product portfolio includes PluriBank™ off-the-shelf iPSC lines available in Ready-to-Differentiate® (RTD®) format, complemented by supporting reagent kits (PluriKit™, PluriFreeze™) and PluriForm™ for organoid generation. The platform integrates key proprietary technologies: FailSafe® (drug-inducible safety switch), iACT Stealth Cells™ (immune cloaking), and footprint-free mRNA reprogramming. Services span custom iPSC generation, differentiated cell production, process development, and GMP manufacturing. The company operates under a Try-Before-You-Buy model via Research Evaluation Agreements, allowing clients to evaluate products before licensing.

Differentiator

Problem solved

Functional benefit

Brands

• panCELLa Platform: iPSC platform for therapeutic development and commercialization
• PluriBank
• PluriForm
• PluriFreeze
• PluriKit
• FailSafe
• iACT Stealth Cells
• Ready-to-Differentiate (RTD)

Products and services

• PluriBank iPSC Lines Off-the-shelf iPSC lines available in Research Use Only (RUO) format, including FailSafe gene edited variants with B2M/CIITA knockouts for enhanced immune evasion and selective ablation mechanism.
• Ready-to-Differentiate (RTD) iPSC and GMP Cell Banks High-density cryopreserved iPSC cell banks frozen at high density that can be turned into product immediately out of thaw, eliminating need for time-intensive pre-differentiation expansion. Available in both research and GMP clinical grade formats.
• PluriForm Kit Ready-to-use kit for generating pluripotent aggregates for organoid applications. Contains 25 million RTD iPSCs that are suspension-adapted and can be seeded in 3D suspension or 2D monolayer culture, generating thousands of pluripotent aggregates within 24 hours.
• PluriFreeze Proprietary cryopreservation system consisting of wash and freezing medium formulations designed for cost-efficient, large-scale, automation-compatible banking processes for cell therapies. Features 2-year shelf stability at room temperature and serum-free, animal component-free formulation.
• PluriKit Integrated reagent solution for reproducible culture of PluriBank RUO FailSafe lines, including Laminin-521 substrate, HiDef-B8 medium, PBS-EDTA dissociation reagent, CEPT cocktail, and PluriFreeze cryopreservation reagent.
• Custom iPSC Service Custom iPSC generation service using proprietary cellular reprogramming technology to create iPSC lines from client-provided somatic cell material, available in Research and Clinical grade with optional FailSafe or iACT Stealth Cells modifications.
• Differentiated Cells Service Stem cell differentiation services to generate derivative cell types from iPSCs, including mesenchymal stem cells and hematopoietic stem cells, using both off-the-shelf and proprietary protocols.
• Development Services Process and analytical development services for iPSC therapy development, including iPSC reprogramming, cell line development and banking, differentiation process improvement, and manufacturing scale-up assistance.
• GMP Manufacturing Phase-appropriate GMP manufacturing services for clinical-grade iPSC production, including cell derivation, reprogramming, Master and Working Cell Bank generation, and tech transfer to CDMO partners.
• Research Evaluation Agreement (REA) Try-Before-You-Buy licensing model allowing clients to evaluate gene edited and non-edited cellular products with smaller upfront costs before entering commercial license agreements.
• Cryopreservation Services End-to-end cryopreservation services including protocol development, optimization, and selection of cell culture media and cryomedia to ensure successful patient administration from laboratory through commercial scale.

Quantifiable outcome

• 70% reduction in development timelines
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

14 partnerships are on record, tiered core and strategic.

• Made ScientificcoreStrategic or Co-development Partner · 4 June 2026Strategic partnership integrating Pluristyx's clinical-grade iPSC platform into Made Scientific's end-to-end CDMO services. Pluristyx serves as iPSC supply and development partner, providing GMP-ready iPSC lines and derivative cell types (iNK, iMSC) under FDA, EMA, and global regulatory compliance. Partnership compresses path to IND filing and reduces redundant quality workstreams.
• CellVoyantstrategicTechnology or Integration · 7 May 2026Strategic partnership to integrate CellVoyant's AI foundation models for live, label-free cell analytics and predictive cell biology with Pluristyx's iPSC technologies for enhanced cell therapy development.
• QkinestrategicChannel Partner/ Reseller/ Distributor · 1 May 2026Reciprocal distribution agreement for optimized growth factor and differentiation products supporting iPSC applications.
• SolesisstrategicTechnology or Integration · 5 February 2026Partnership to launch PluriForm GFP-3D Transfection Kit for 3D iPSC transfection with ready-to-use system eliminating complex optimization steps.
• MytosstrategicStrategic or Co-development Partner · 11 December 2025Strategic collaboration to manufacture GMP line for regenerative medicines.
• Organoid COMMONS ConsortiumstrategicStrategic or Co-development Partner · 2 December 2025Consortium involving ten industry partners aimed at establishing global standards for organoid development to support drug discovery and regulatory acceptance, replacing animal testing with human-relevant organoid models.
• Breakthrough T1D (formerly JDRF)coreStrategic or Co-development Partner · 17 November 2025Collaboration supported by Breakthrough T1D funding up to $1.4 million to develop a genetically engineered iPSC line with immune-cloaking (iACT) and safety switch (FailSafe) technologies for Type 1 Diabetes therapies. Project creates universal, off-the-shelf islet cell therapies not requiring immunosuppression.
• National ResiliencecoreStrategic or Co-development Partner · 1 March 2024Collaboration to streamline transition of promising iPSC-derived therapies from benchtop to bedside, combining Pluristyx's gene-edited iPSC expertise with Resilience's biomanufacturing capabilities.
• Charles RivercoreChannel Partner/ Reseller/ Distributor · 8 February 2024Agreement providing Charles River broad access to highly characterized stem cell lines including high-quality embryonic stem cells and iPSCs as research tools to support development of new therapeutics.
• TeknovacoreChannel Partner/ Reseller/ Distributor · 20 September 2023Collaboration agreement with Teknova for manufacture and commercialization of Pluristyx's proprietary PluriFreeze cryopreservation system, including wash and storage products, in the US and Canada. Teknova helps expand access to this novel cryopreservation solution.
• Stem GenomicsstrategicStrategic or Co-development Partner · 1 July 2023Strategic partnership with equity investment combining Pluristyx's iPSC lines with Stem Genomics' iCS-digital PSC assay for genomic stability evaluation of pluripotent stem cell lines.
• Advanced Regenerative Manufacturing Institute (ARMI) / BioFabUSAstrategicStrategic or Co-development Partner · 1 July 2023Agreement to manufacture and commercialize Pluristyx's clinical-grade reprogrammed iPSCs, leveraging ARMI's manufacturing capabilities.
• California Institute for Regenerative Medicine (CIRM)strategicStrategic or Co-development Partner · 1 June 2023Industry Resource Partner (IRP) status providing CIRM awardees improved access to Pluristyx's highly-characterized and genetically-modified iPSCs containing FailSafe and iACT technologies.
• StemmattersstrategicStrategic or Co-development Partner · 1 May 2023Collaboration focused on advancement of next-generation iPSC-derived Mesenchymal Stem Cells (iMSCs), engineered iMSCs, and biological products including exosomes and conditioned media with large-scale manufacturing capabilities.

Scale indicators4 records

Expansion highlights6 records

Others

• Corning Life Sciences: Supplier of cell culture vessels, surfaces (Corning Matrigel alternatives), and bioprocess containers used in iPSC workflows. Enabling technology partner/competitor in cell culture substrates.

Emerging players

• Fate Therapeutics: iPSC-derived NK and T-cell therapy developer with proprietary iPSC platform. Potential large customer for Pluristyx iPSC lines and licensing, while also a competitor in the iPSC-derived therapy space.
• Century Therapeutics: Clinical-stage iPSC-derived allogeneic cell therapy developer (iNK, iT platforms) with in-house iPSC engineering. Both customer and competitor — Pluristyx licensing could enable or compete with Century's internal platform.

Broad incumbents

• Bio-Techne: Major life sciences reagents and tools provider with significant stem cell and cell therapy product portfolio (R&D Systems, ProteinSimple). Overlaps with Pluristyx's consumables and reagent offerings.
• Lonza Cell & Gene Technologies: Global CDMO with major cell and gene therapy manufacturing capabilities including iPSC process development and GMP manufacturing. Overlaps with Pluristyx's GMP manufacturing and CDMO partnership activity.
• STEMCELL Technologies: Large life sciences tools provider specializing in cell culture media, reagents, and instruments for stem cell research. Competes with Pluristyx's PluriKit™ and PluriFreeze™ consumables lines.
• Thermo Fisher Scientific (Cell Therapy): Diversified life sciences leader with cell culture media, Gibco reagents, and Patheon CDMO services competing across Pluristyx's consumables, services, and manufacturing offerings.

Direct peers

• bit.bio: UK-based iPSC platform company providing opti-ox™ reprogramming technology for consistent iPSC-derived cell products at scale. Competes directly in iPSC reprogramming and cell banking for therapeutic and research use.
• Ncardia: Belgium-based iPSC-derived cell products and services company (cardiac, neural, immune cells) serving drug discovery and cell therapy developers. Closest mid-stage direct peer in offering structure.
• FUJIFILM Cellular Dynamics: Long-standing iPSC line and differentiated cell provider (iCell cardiomyocytes, neurons, hepatocytes) acquired by Fujifilm. Direct competitor in iPSC-derived cell products and GMP banking services.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pluristyx

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pluristyx